Reflux Esophagitis
Conditions
Keywords
Reflux esophagitis, Omepral®, QOLRAD
Brief summary
This open label, non-interventional study is to compare the efficacy of Omepral® tablet and any other treatments excepting proton pump inhibitors (PPIs) for the treatment of various type of acid reflux related symptoms in patients with reflux esophagitis.
Interventions
None listed
Sponsors
AstraZeneca
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Patients newly diagnosed as erosive esophagitis or history of erosive esophagitis confirmed by endoscopy. * Patients who answered questionnaires of quality of life (QOLRAD-J), symptom severity and frequency and treatment satisfaction. * During the past 1 week , patients who have either two days or more with heartburn or acid taste in the mouth of any severity
Exclusion criteria
* Patients receiving treatment with proton pump inhibitors, which make stomach acid decreased during the last 4 weeks prior to enrolment. * Patients who cannot answer questionnaires of quality of life (QOLRAD-J), symptom severity and frequency and treatment satisfaction. * Patients included previously in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patients symptom evaluated by investigator | at entry, 4 weeks and 8 weeks |
| Patients reported symptom | at entry, 4 weeks and 8 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Patients reported outcome score | at entry, 4 weeks and 8 weeks |
| Adverse event | 8 weeks |
Outcome results
None listed